Henry Schein: Take a Bite Out of the Rally — A Swing Trade With Room to Run

Hook & thesis

Henry Schein (HSIC) has quietly rebuilt momentum: the stock is inside striking distance of its 52-week high while the underlying business is benefiting from structural demand in dental and medical consumables and a growing addressable market in clear aligners. Recent operational moves - a $200 million efficiency plan, active buybacks and an expanded KKR partnership - give management levers to convert revenue growth into measurable earnings improvement. For traders willing to accept modest balance-sheet leverage and some execution risk, HSIC offers a controlled way to participate in both cyclical recovery and secular tailwinds.

My trade idea: buy HSIC at $80.00 with a stop at $73.00 and a target of $92.00. This is a swing trade intended to play through improving fundamentals and near-term technical momentum over a mid-term horizon: 45 trading days. Risk is real here, but reward and catalysts are visible and measurable.

What the company does and why the market should care

Henry Schein is a global distributor of healthcare products and services to office-based practitioners in dental, medical and veterinary markets. It operates three segments: Global Distribution and Value-Added Services, Global Specialty Products (including implants and biomaterials), and Global Technology (practice-management software and e-services). Distribution businesses like HSIC generate recurring revenue, predictable working-capital dynamics and healthy free cash flow when volume stabilizes.

Why investors should care now: the orthodontics/clear-aligner market is expanding rapidly, with multiple industry reports showing high-teens-to-30% CAGRs through the decade. That market growth sits squarely in HSIC's distribution and specialty product opportunity set. On the operational side, management has announced a $200 million efficiency program and returned capital aggressively with $229 million in buybacks during a recent quarter - actions that should boost EPS if executed.

Supporting numbers

Recent operational datapoints are constructive. A reported quarter showed sales of $3.34 billion and adjusted EPS of $1.38, with management raising the outlook after expanding a strategic partnership with KKR on 11/04/2025. Those numbers tell a story of modest top-line growth (reported 5% revenue growth in the quarter) and operational leverage that can accelerate as efficiency initiatives take hold.

On the liquidity and capital-allocation front, management repurchased $229 million of stock during the quarter, while announcing a $200 million efficiency program that should convert to tangible margin improvement if execution remains disciplined. Free cash flow of about $445 million gives the company runway to buy back more shares or pay down expensive liabilities if needed.

Valuation framing

At a market cap of about $9.1 billion and an EV of roughly $12.37 billion, HSIC trades at approximately 0.68x price-to-sales and 11.6x EV/EBITDA. That places the company in the attractive mid-single-digit enterprise multiple territory for a distributor with steady recurring product flows and visible secular end-markets. A P/E near 23x factors in the company’s recent earnings base (earnings per share around $3.47) and assumes continued margin recovery; the announced efficiency program and buybacks are the levers likely to justify that multiple if results follow through.

Put simply: the stock’s multiple isn't stretched given the combination of FCF generation ($445M), a constructive revenue backdrop and a credible margin-improvement plan. The gap to the 52-week high ($89.29) is modest, leaving room for a tactical swing that capitalizes on momentum and visible catalysts.

Catalysts (near-term to mid-term)

• Execution of the $200 million efficiency plan - measurable margin expansion and upside to EPS guidance.
• Momentum in the clear-aligner and invisible orthodontics market supporting higher specialty-product volumes (industry reports show strong multi-year growth).
• Ongoing buybacks and partnership synergies with KKR that can accelerate share repurchase and transform capital allocation.
• Sequential margin recovery in dental operations following earlier pressure; a swing in margins materially moves EPS given current revenue base.

Trade plan (actionable)

Entry: buy HSIC at $80.00.

Stop: $73.00 — placed beneath the 50-day moving average ($75.80) and below the recent consolidation area; if price breaks this level, it signals the momentum case failed.

Target: $92.00 — a mid-term target that sits above the 52-week high of $89.29 and reflects a realistic upside if catalysts accelerate earnings and sentiment improves.

Horizon: mid-term (45 trading days). This timeline balances the time needed for efficiency savings to be reported or teased out in quarterly updates, while not holding through a prolonged macro drawdown. The setup combines technical momentum — recent 10/20/50-day SMAs are ascending and RSI sits around 62 — with fundamental catalysts that typically resolve on a quarterly cadence.

Position sizing: treat this as a tactical swing; size accordingly given the stop placement and your portfolio risk tolerance.

Risks and counterarguments

• Execution risk on the efficiency plan - if the $200 million program stalls or costs are front-loaded without realizing savings, margins could compress further and EPS guidance could be cut.
• Dental-margin pressure can persist - dental operations have historically driven earnings swings and a slower recovery in dental procedure volumes or pricing could weigh on results.
• Leverage and liquidity - debt-to-equity of ~1.04 is elevated for a distributor; a macro shock or working-capital stress could make debt servicing more painful and limit buybacks.
• Reputational/legal risk - negative publicity (for example, the reported allegation of misconduct in a lab business) could erode customer trust or invite regulatory scrutiny that is costly to resolve.
• Macro/industry cyclical risk - as a distributor, HSIC is exposed to procedure volumes and capex in dental/medical practices; a weak macro backdrop or reduced elective procedures would impact sales and cash flow.

Counterargument to the bullish thesis: One could reasonably argue that most positive catalysts are already priced in. The stock is near its 52-week high, management has already signaled improvement, and the market may have front-run much of the efficiency plan and buyback benefit. If broader market multiples compress or the company reports only modest incremental margin gains, upside could be limited and the stock could drift or correct back toward the mid-$60s to low-$70s.

What would change my mind

I would abandon the bullish trade if any of the following occur: 1) management retracts guidance or warns materially on the efficiency program; 2) a quarter shows renewed shrinkage in dental margins without a pathway to recovery; 3) leverage trends materially worse with cash-flow impairment that forces an abrupt halt to buybacks. Conversely, I would add to the position if management reports clear, quantifiable savings from the efficiency plan, guidance is raised, or M&A/partnership activity meaningfully expands the addressable market.

Conclusion

HSIC presents a pragmatic swing-trade opportunity: strong secular tailwinds in orthodontics and clear aligners, an active capital-allocation program, and improving technicals. The valuation is reasonable for a distributor with stable cash flow and visible margin levers. The trade is not risk-free - execution on efficiency and dental-margin recovery are the keys - but by defining entry, stop and target precisely, traders can take a measured long exposure while capping downside. Buy at $80.00, stop at $73.00, target $92.00 over 45 trading days; adjust size to your risk limits and watch the next two quarters for execution evidence.

Key dates referenced

• Management raised outlook and expanded KKR partnership - 11/04/2025.
• Quarter showing revenue $3.34B and adjusted EPS $1.38 - reported in the quarter leading up to 11/04/2025.
• Q2 EPS decline reported - 08/05/2025.